Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genfleet Therapeutics (Shanghai), Inc. Class H ( (HK:2595) ) has shared an update.
GenFleet Therapeutics will present preclinical data for three RAS pathway-targeted compounds—GFH276, GFS784 and GFH603—at the 2026 American Association for Cancer Research Annual Meeting in San Diego. The portfolio covers both large- and small-molecule modalities, including a non-degrading molecular glue, an antibody-drug conjugate and a molecular glue-like covalent allosteric activator, underscoring its broad RAS-targeted matrix and ambitions in oncology innovation.
By showcasing this trio of differentiated RAS-focused therapies at a major global cancer research forum, GenFleet aims to highlight the depth of its pipeline and strengthen its positioning in the competitive targeted oncology space. The visibility from AACR may support the company’s efforts to attract partners and investors, while the diversified mechanisms of action could enhance its long-term prospects in addressing complex RAS-driven cancers.
More about Genfleet Therapeutics (Shanghai), Inc. Class H
GenFleet Therapeutics (Shanghai) Inc. is a China-based biopharmaceutical company focused on developing new treatment options for oncology, autoimmune and inflammatory diseases to address unmet medical needs globally. It operates an integrated research and development platform spanning target and molecular discovery, translational science, clinical development and key manufacturing functions, supporting a pipeline positioned among frontrunners in China and international markets.
Average Trading Volume: 1,341,204
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$9.63B
See more data about 2595 stock on TipRanks’ Stock Analysis page.